ORKA
Oruka Therapeutics, Inc. NASDAQ$66.46
Pre-mkt
$67.11
+0.98%
Mkt Cap $2.5B
52w Low $8.91
70.1% of range
52w High $91.00
50d MA $49.75
200d MA $30.66
P/E (TTM)
-27.1x
EV/EBITDA
-11.0x
P/B
6.0x
Debt/Equity
0.0x
ROE
-22.3%
P/FCF
-15.6x
RSI (14)
—
ATR (14)
—
Beta
-0.61
50d MA
$49.75
200d MA
$30.66
Avg Volume
906.0K
About
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | -0.61 | -0.45 | +26.2% | 31.99 | +2.7% | +25.0% | +30.5% | +29.1% | +27.5% | +21.4% | — |
| Nov 12, 2025 | AMC | -0.56 | -0.55 | +1.8% | 28.30 | +5.3% | -6.8% | -4.3% | -0.2% | -3.0% | -0.1% | — |
| Aug 11, 2025 | AMC | -0.48 | -0.46 | +4.2% | 13.05 | +1.3% | +6.9% | +17.5% | +14.9% | +17.8% | +16.9% | — |
| May 14, 2025 | AMC | -0.57 | -0.40 | +29.8% | 9.71 | +8.0% | -2.6% | +3.6% | +6.2% | +9.4% | +9.0% | — |
| Mar 6, 2025 | AMC | -0.68 | -0.49 | +27.9% | 10.07 | -0.9% | +3.9% | +8.6% | +9.8% | +14.7% | +10.6% | — |
| Nov 13, 2024 | AMC | -0.40 | -1.46 | -265.0% | 25.65 | -3.0% | -6.4% | -6.3% | -17.6% | -13.1% | -13.5% | — |
| Aug 27, 2024 | AMC | — | -1.53 | — | 46.56 | -0.8% | -10.1% | -35.6% | -38.1% | -45.2% | -39.9% | — |
| Apr 25, 2024 | AMC | — | -0.14 | — | 41.76 | +5.7% | +2.9% | -1.4% | +0.3% | -6.6% | -6.3% | — |
| Dec 31, 2023 | AMC | — | -0.08 | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | — | -0.10 | — | — | — | — | — | — | — | — | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28 | Barclays | Maintains | Overweight → Overweight | — | $76.39 | $78.21 | +2.4% | -3.1% | -10.9% | -10.4% | -18.1% | — |
| Apr 28 | UBS | Maintains | Buy → Buy | — | $76.39 | $78.21 | +2.4% | -3.1% | -10.9% | -10.4% | -18.1% | — |
| Apr 27 | BTIG | Maintains | Buy → Buy | — | $69.03 | $90.02 | +30.4% | +10.7% | +7.2% | -1.3% | -0.9% | -9.3% |
| Apr 15 | Wedbush | Maintains | Outperform → Outperform | — | $67.06 | $67.45 | +0.6% | -2.3% | +0.0% | +2.8% | +2.7% | +2.9% |
| Apr 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $59.58 | $60.16 | +1.0% | +3.0% | +12.6% | +10.0% | +12.6% | +15.7% |
| Apr 13 | Guggenheim | Maintains | Buy → Buy | — | $59.58 | $60.16 | +1.0% | +3.0% | +12.6% | +10.0% | +12.6% | +15.7% |
| Apr 13 | BTIG | Maintains | Buy → Buy | — | $59.58 | $60.16 | +1.0% | +3.0% | +12.6% | +10.0% | +12.6% | +15.7% |
| Apr 9 | Guggenheim | Maintains | Buy → Buy | — | $62.01 | $62.60 | +1.0% | +2.6% | -3.9% | -1.0% | +8.1% | +5.7% |
| Apr 7 | Barclays | Maintains | Overweight → Overweight | — | $56.37 | $56.28 | -0.2% | +7.5% | +10.0% | +12.8% | +5.7% | +8.9% |
| Apr 6 | Guggenheim | Maintains | Buy → Buy | — | $53.31 | $55.00 | +3.2% | +5.7% | +13.7% | +16.3% | +19.3% | +11.8% |
Recent Filings
Data updated apr 26, 2026 5:53pm
· Source: massive.com